CARVYKTI (ciltacabtagene autoleucel)
Named by the company as a Q2 2026 growth driver in multiple myeloma CAR-T therapy.
What it is
CAR-T cell therapy for relapsed or refractory multiple myeloma, developed with Legend Biotech. It is a key growth driver in oncology. The company gives no dollar sales figure for it in the Q2 2026 release.
Why it matters to the stock. A cell therapy with high growth potential, but manufacturing capacity and reimbursement decide how fast it can scale.
News
J&J commits more than $1 billion to a next-generation cell therapy plant in Montgomery County, Pennsylvania
Johnson & Johnson announced a manufacturing investment of more than $1 billion in a next-generation cell therapy facility in Montgomery County, Pennsylvania.
Capital